Company Profile

Kylin Therapeutics Inc
Profile last edited on: 4/22/19      CAGE: 4Q4U7      UEI:

Business Identifier: RNA interference-based therapeutics
Year Founded
2003
First Award
2009
Latest Award
2009
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3000 Kent Avenue
West Lafayette, IN 47906
   (765) 269-8030
   N/A
   www.kylintherapeutics.com
Location: Single
Congr. District: 04
County: Tippecanoe

Public Profile

Kylin Therapeutics Inc had been biotechnology company with ties to Purdue University, employing a revolutionary RNA nanoparticle technology platform called "pRNA" to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. The platform offered the potential of meeting the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform seemed to have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies but by mid-2012, the firm had ceased operations

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2009 1 NIH $200,000
Project Title: Prna Nanoparticles For Therapeutic Use

Key People / Management

  Eric Davis -- President and CEO

  Peixiuan Guo

  Henry Li -- Director of R&D

  Joseph P Trebley

Company News

There are no news available.